High-throughput Diagnostics and Sequencing at the Pandemic Response Lab NYC

Explore a keynote presentation on high-throughput diagnostics and sequencing at the Pandemic Response Lab in New York City. Delve into the efforts to control the spread of SARS-CoV-2 through widespread testing and monitoring of emerging variants. Learn about the CoV2 test principle, virus inactivation, RNA extraction, and sample processing pipeline. Discover the equipment stoichiometry, sample tracking, and analysis using the DaViD system. Examine current optimization work, including pooled testing and at-home saliva collection. Investigate the integrated CoV2 whole genome sequencing pipeline, development timeline, and variant growth over time. Analyze NYC variant distributions, focusing on B.1.1.7 and B.1.526 +E484K strains. Gain insights into the executive team, Scientific Advisory Board, and the dedicated professionals behind these crucial pandemic response efforts.

Intro
The CoV2 test principle is straightforward How do we make it high throughput?
CoV2 test steps
CoV2 assay targets
CoV2 assay details
Test development timeline
Virus inactivation
RNA extraction
Sample processing pipeline - throughput
Equipment stoichiometry - one 'line' PRL NYC has three lines operating
Sample tracking and analysis - DaViD
Future of sample tracking
DaViD-analysis interface
Test statistics
Current optimization work
Changing sample collection paradigm
Pooled testing
At-home saliva collection
What's next for PRL testing?
CoV2 whole genome sequencing
Sequencing pipeline is integrated into the testing line
Sequencing pipeline overview
Sequencing development timeline
GISAID submissions by state
Variant growth over time
NYC variant sequences from PRL
NYC variant distributions from PRL
NYC variant distributions - B.1.1.7
NYC variant distributions - B.1.526 +E484K
PRL testing vs sequencing distribution
Executive team
Scientific Advisory Board
The team that does it all